Financial Information for the Year Ended March 31, 2021

As of May 12, 2021

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

(Note about forward-looking information)
The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

Table of Contents

1 Summary of Financial Results for FY2020 and Forecasts for FY2021

<Regarding GILENYA Royalty>

As Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced on April 24, 2019 in the "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019", MTPC is currently in the arbitration proceedings with Novartis Pharma AG (hereinafter "Novartis"), and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts, which correspond to the clauses in the 1997 License Agreement of which Novartis has protested the validity, as our revenue because such payments do not satisfy one of the requirements under IFRS15, i.e., "Revenue under contract with customers". During the period of the arbitration proceedings, MTPC will continue the same accounting practice as MTPC did in fiscal year 2018. For fiscal year 2021, the forecast is prepared on the assumption that the arbitration procedure to continue.
MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration. As for the amounts among the GILENYA Royalty amounts which will not be recognized as sales revenue, those will be recognized as revenue at the end of the arbitration, depending on the outcome of the arbitration.

1. Summary of Financial Results for FY2020

(Amounts less than ¥100 million are rounded)

[Billion yen]

Revenue	377.8	Y-on-Y	(2.1)	(0.5 %)
Domestic	313.0	Y-on-Y	(1.0)	(0.3 %)
Overseas	64.8	Y-on-Y	(1.1)	(1.6 %)

Domestic ethical drugs sales increased by 0.1% to ¥304.7 billion, due to increase of SIMPONI for Rheumatoid arthritis (RA) etc. treatment, CANAGLU and CANALIA for type 2 diabetes mellitus, RUPAFIN for allergy treatment, vaccines, as well as contribution of STELARA additionally approved for UC, despite NHI price revision in April 2020 and increasing usage of generic drugs treatment.
Royalty revenue, etc. decreased by 8.9% to ¥15.9 billion due to the decline in royalty revenue from GILENYA for multiple sclerosis treatment licensed to Novartis, etc.

[Billion yen]

Core Operating Profit*1	21.0	Y-on-Y	2.0	10.4 %

Core operating profit increased due to SG&A and R&D expenses contained by voluntary restraint in activities under COVID-19 spread.

[Billion yen]

Operating Profit*2	(58.5)	Y-on-Y	(52.4)	-

As for non-recurring items;
Profitability of NeuroDerm's projects for Parkinson's Disease is expected to decline due to delayed clinical study and the competitors' development status. As a result of reviewing the business plan based on the results of recent market research, we recorded an impairment loss of ¥84.5 billion for intangible assets related to above projects. Gain from fixed assets in transfer of Toda office, etc. booked ¥8.1 billion as well.

[Billion yen]

Profit before tax for the period*2	(57.7)	Y-on-Y	(51.2)	-
Net Income Attributable to owners of the Company*2	(46.9)	Y-on-Y	(47.0)	-

2. Summary of Forecasts for FY2021

[Billion yen]

Revenue	407.5	Y-on-Y	29.7	7.9 %
Core Operating Profit	26.0	Y-on-Y	5.0	23.6 %
Operating Profit	30.0	Y-on-Y	88.5	-
Net Profit Attributable to owners of the Company	17.5	Y-on-Y	64.4	-

Sales of domestic ethical drugs are expected to decrease due to the impact of the NHI drug price revision, despite growth of priority products. On the other hand, total revenue is expected to increase due to a presumption of commercialization of Medicago's COVID-19 vaccine.
Core operating profit is expected to increase due to sales growth, despite increased R&D costs for late-stage projects such as COVID-19 vaccine and increased expenses for preparation of sales of new products in and outside Japan.
Operating profit and net profit attributable to owners of the company are expected to increase due primarily to the vanishment of impairment loss of ¥84.5 billion from NeuroDerm projects in the previous year.

*1 With adoption of IFRS, the Company, its subsidiaries and its affiliates (collectively, "the Group") has introduced "core operating profit" as a major profit index to demonstrate its recurring profitability and positioned as an important indicator of business management, etc. "Core operating profit" is a profit excluding the income and loss recorded by non-recurring items specified by the Group (hereinafter "non-recurring items") from operating profit. The Company assumes gain or loss associated with a business transfer, restructuring loss, impairment losses on intangible assets associated with products and others as non-recurring items.

*2 Brackets indicate expense and loss

2 Consolidated Financial Indicators for FY2020

(Amounts less than ¥100 million are rounded)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	FY2020	Comparison to previous year			Comparison to Forecasts			Notes [Y-on-Y comparison]
		FY2019	Increase (decrease)	Change %	Forecasts*1	Increase (decrease)	Progress %	
Revenue	**377.8**	379.8	(2.1)	(0.5)	373.0	4.8	1.3	Refer to "(2) Sales Revenue of Main Products"
Domestic	**313.0**	314.0	(1.0)	(0.3)	312.2	0.8	0.3	
Overseas	**64.8**	65.8	(1.1)	(1.6)	60.8	4.0	6.5	
Overseas sales ratio	**17.1%**	17.3%			16.3%			
Cost of sales	**190.4**	181.0	9.3	5.2	187.5	2.9	1.5	Deteriorated by NHI price revision, etc.
Sales cost ratio	**50.4%**	47.7%			50.3%			
Gross profit	**187.4**	198.8	(11.4)	(5.7)	185.5	1.9	1.0	
SG&A expenses, etc.	**166.4**	179.7	(13.4)	(7.4)	168.5	(2.1)	(1.3)	Decrease by shrinkage in activities, etc. under COVID-19 pandemic
R&D expenses	**72.6**	79.4	(6.9)	(8.7)	72.5	0.1	0.1	
Core operating profit	**21.0**	19.1	2.0	10.4	17.0	4.0	23.7	
Non-recurring items*2	**(79.6)**	(25.1)	(54.4)	-	(79.5)	(0.1)	-	
Gain from sales of Toda office	**7.5**	-	7.5	-				
Arbitration award with KLS	**4.1**	-	4.1	-				
Impairment loss*3	**(88.4)**	(24.1)	(64.3)	-				
Operating profit*2	**(58.5)**	(6.1)	(52.4)	-	(62.5)	4.0	-	
Financial income and loss*2	**0.8**	(0.4)	1.2	-				
Profit before tax for the period*2	**(57.7)**	(6.5)	(51.2)	-	(62.0)	4.3	-	
Income taxes	**(7.1)**	2.9	(10.0)	-				
Net profit for the period*2	**(50.6)**	(9.4)	(41.2)	-	(55.0)	4.4	-	
Net profit attributable to owners of the Company*2	**(46.9)**	0.1	(47.0)	-	(52.5)	5.6	-	

[Yen]

Exchange rate	FY2020 average	FY2019 average	FY2020 planned
USD	**105.94**	108.95	108.00

Effect of fluctuations in exchange rate for FY2020: Revenue decreased by ¥0.7 billion and core operating profit increased by ¥2.0 billion.

(2) Sales Revenue of Main Products

[Billion yen]

	FY2020	Comparison to previous year			Comparison to Forecasts		
		FY2019	Increase (decrease)	Change %	Forecasts*1	Increase (decrease)	Progress %
Domestic ethical drugs	**304.7**	304.4	0.3	0.1	302.3	2.4	0.8
Priority products	**183.0**	177.1	5.9	3.3	183.0	0.0	0.0
Remicade	**45.4**	53.4	(8.0)	(15.0)	45.0	0.4	0.8
Simponi	**42.3**	41.0	1.4	3.4	42.7	(0.4)	(0.8)
Stelara	**32.2**	26.0	6.2	23.8	31.9	0.3	1.0
Tenelia	**15.1**	15.2	(0.1)	(0.8)	14.9	0.2	1.3
Canaglu	**10.3**	8.8	1.5	16.6	9.8	0.5	5.3
Canalia	**9.7**	6.7	3.0	44.6	9.3	0.4	4.7
Vafseo (launched in Aug.)	**0.3**	-	0.3	-	0.5	(0.2)	(31.2)
Lexapro	**15.3**	15.0	0.4	2.5	14.8	0.5	3.6
Rupafin	**8.2**	6.8	1.4	20.7	10.0	(1.8)	(18.3)
Imusera	**4.1**	4.2	(0.1)	(3.3)	4.1	0.0	0.1
Vaccines	**42.6**	39.0	3.6	9.3	41.6	1.0	2.5
Influenza vaccine	**14.4**	12.6	1.8	14.0	13.2	1.2	9.1
Tetrabik	**10.9**	9.5	1.5	15.4	11.1	(0.2)	(1.4)
Mearubik	**6.1**	6.0	0.2	2.9	6.4	(0.3)	(4.3)
JEBIK V	**5.2**	5.2	0.0	0.4	5.3	(0.1)	(2.3)
Varicella vaccine	**5.0**	4.9	0.0	0.5	4.8	0.2	3.2
Long-listed drugs, etc.	**79.0**	88.3	(9.3)	(10.5)	77.7	1.3	1.7
Overseas ethical drugs	**50.2**	49.7	0.5	1.0	47.0	3.2	6.8
Radicava	**22.0**	23.1	(1.2)	(5.1)	20.1	1.9	9.2
Royalty revenue, etc.	**15.9**	17.4	(1.5)	(8.9)	15.2	0.7	4.5
Royalty from INVOKANA	**9.1**	8.5	0.6	6.8	Undisclosed	-	-
Royalty from GILENYA*4	**4.3**	5.7	(1.4)	(24.4)	Undisclosed	-	-

*1: Forecasts announced on Feb. 3, 2021

*2: Brackets indicate expense and loss

*3: 84.5 from NeuroDerm projects in Q2 and 3.9 from MT-5745(STNM01)

*4: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

2. Financial Statement

(1) Balance Sheet

[Billion yen]

	End of FY2020	End of FY2019	Increase (decrease)	Notes
Assets	**1,053.3**	1,046.3	7.0	
Non-current assets	**378.4**	452.8	(74.4)	
Property, plant and equipment	**82.1**	86.1	(4.0)	Obtain 18.6, depreciation(11.1), etc.
Goodwill	**90.6**	89.7	0.9	
Intangible assets	**91.1**	181.3	(90.3)	Impairment loss 84.5 from NeuroDerm's projects, etc.
Current assets	**674.8**	593.5	81.4	
Inventories	**81.7**	80.3	1.4	
Trade and other receivables	**116.0**	108.6	7.4	
Other financial assets	**330.1**	300.3	29.8	
Cash and cash equivalents	**114.2**	83.1	31.2	Refer to "(2) Cash Flow Statement"
Liabilities	**236.4**	188.4	48.0	
Non-current liabilities	**108.6**	90.3	18.3	
Other non-current liabilities	**77.5**	40.9	36.6	
Current liabilities	**127.8**	98.0	29.8	
Trade and other payables	**29.5**	32.1	(2.6)	
Equity	**816.9**	857.9	(41.0)	
Share capital	**50.0**	50.0	-	
Capital surplus	**448.0**	448.0	(0.1)	
Retained earnings	**313.3**	358.4	(45.1)	Net loss for the period 46.9, etc.

(2) Cash Flow Statement

[Billion yen]

	FY2020	FY2019	Increase (decrease)
Cash and cash equivalents at beginning of year	**83.1**	111.9	(28.8)
Cash flows from operating activities	**67.8**	49.4	18.4
Profit before tax*	**(57.7)**	(6.5)	(51.2)
Depreciation and amortization	**15.2**	15.3	(0.2)
Impairment loss	**88.4**	24.1	64.3
Loss on sales of Property, Plant and Equipment	**(8.1)**	-	(8.1)
Trade receivable and payable	**(9.8)**	9.5	(19.4)
Other	**39.8**	6.9	32.9
Cash flows from investing activities	**(31.9)**	(39.2)	7.4
Purchase (proceeds from sales) of property, plant and equipment	**(3.1)**	(10.7)	7.6
Purchase (Proceeds from sales) of investments	**64.1**	97.6	(33.5)
Increase in deposits	**(95.2)**	(120.0)	24.9
Other	**2.3**	(6.1)	8.4
Cash flows from financing activities	**(7.2)**	(37.9)	30.6
Effect of exchange rate changes on cash and cash equivalents	**2.5**	(1.2)	3.7
Net increase(decrease) in cash and cash equivalents	**31.2**	(28.9)	60.1
Increase (decrease) by transfer to assets held for sales	**-**	0.1	(0.1)
Cash and cash equivalents at the end of period	**114.2**	83.1	31.2

*Brackets indicate loss

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

Occurring basis	FY2020	FY2019	Increase (decrease)
Investment in property, plant and equipment	**18.6**	14.1	4.5
Investment in information systems	**1.4**	1.4	(0.0)

(4) Depreciation and Amortization Costs

[Billion yen]

	FY2020	FY2019	Increase (decrease)
Property, plant and equipment	**11.1**	7.0	4.1
Intangible assets	**1.2**	1.5	(0.2)
Intangible assets with products	**2.8**	2.5	0.3

3 Forecasts for FY2021

(Amounts less than ¥ 100 million are rounded)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	FY2021 forecasts	Comparison to previous year			Notes [Y-on-Y Comparison]
		FY2020 actual	Increase (decrease)	Change %	
Revenue	**407.5**	377.8	29.7	7.9	Refer to "(2) Sales Revenue Forecasts for Main Products"
Domestic	**296.1**	313.0	(17.0)	(5.4)	
Overseas	**111.4**	64.8	46.7	72.1	
Overseas sales ratio	**27.3%**	17.1%			
Cost of sales	**192.5**	190.4	2.1	1.1	
Sales cost ratio	**47.2%**	50.4%			
Gross profit	**215.0**	187.4	27.6	14.7	
SG&A expenses, etc.	**189.0**	166.4	22.6	13.6	Increase due to preparation costs for launch of new products, etc.
R&D expenses	**85.0**	72.6	12.4	17.2	Increase in globally late stage development costs, etc.
Core operating profit	**26.0**	21.0	5.0	23.6	
Non-recurring items*1	**4.0**	(79.6)	83.6	-	Impairment loss 84.5 from NeuroDerm's projects in FY2020
Operating profit*1	**30.0**	(58.5)	88.5	-	
Net profit attributable to owners of the Company*1	**17.5**	(46.9)	64.4	-	

Exchange rate

[Yen]

	FY2021 planned	FY2020 average
USD	**108.00**	105.94

(2) Sales Revenue Forecasts for Main Products

[Billion yen]

	FY2021 forecasts	Comparison to previous year		
		FY2020 actual	Increase (decrease)	Change %
Domestic ethical drugs	**286.3**	304.7	(18.3)	(6.0)
Priority products	**145.3**	137.7	7.6	5.5
Simponi	**41.2**	42.3	(1.1)	(2.7)
Stelara	**42.7**	32.2	10.5	32.4
Tenelia	**14.4**	15.1	(0.7)	(4.6)
Canaglu	**10.1**	10.3	(0.2)	(2.1)
Canalia	**9.3**	9.7	(0.4)	(4.2)
Vafseo	**1.3**	0.3	1.0	278.5
Lexapro	**14.1**	15.3	(1.3)	(8.2)
Rupafin	**8.9**	8.2	0.7	9.0
Imusera	**3.3**	4.1	(0.8)	(19.7)
Vaccines	**37.0**	42.6	(5.6)	(13.1)
Influenza vaccine	**14.3**	14.4	(0.1)	(0.8)
Tetrabik	**10.8**	10.9	(0.2)	(1.5)
Mearubik	**5.7**	6.1	(0.5)	(7.5)
JEBIK V	**1.3**	5.2	(3.9)	(75.8)
Varicella vaccine	**4.1**	5.0	(0.8)	(16.8)
Long-listed drugs, etc.	**104.0**	124.4	(20.4)	(16.4)
Remicade*2	**36.5**	45.4	(8.8)	(19.4)
Overseas ethical drugs	**100.6**	50.2	50.4	100.3
Radicava	**19.2**	22.0	(2.7)	(12.4)
Royalty revenue, etc.	**12.3**	15.9	(3.6)	(22.6)
Royalty from INVOKANA	**Undisclosed**	9.1	-	-
Royalty from GILENYA*3	**Undisclosed**	4.3	-	-

*1: Brackets indicate expense and loss

*2: Classified from priority product to long-listed drugs, etc. in FY2021. Figures in FY2020 was adjusted along with this for comparison.

*3: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021 forecasts
Revenues	424.0	433.9	424.8	379.8	377.8	407.5
Cost of sales	164.4	169.8	180.6	181.0	190.4	192.5
Gross profit	259.6	264.1	244.1	198.8	187.4	215.0
SG&A expenses, etc.	165.1	185.6	188.3	179.7	166.4	189.0
R&D expenses	64.8	79.1	86.5	79.4	72.6	85.0
Core operating profit	94.5	78.5	55.8	19.1	21.0	26.0
Operating profit	94.1	77.3	50.3	(6.1)	(58.5)	30.0
Net profit attributable to owners of the Company	71.3	58.0	37.4	0.1	(46.9)	17.5

(2) Balance Sheet

[Billion yen]

	End of FY2016	End of FY2017	End of FY2018	End of FY2019	End of FY2020
Assets	984.5	1,048.4	1,056.3	1,046.3	1,053.3
Non-current assets	300.8	462.9	467.9	452.8	378.4
Current assets	683.8	585.5	588.4	593.5	674.8
Liabilities	113.1	153.6	146.0	188.4	236.4
Non-current liabilities	24.7	55.4	54.3	90.3	108.6
Current liabilities	88.4	98.2	91.7	98.0	127.8
Equity	871.4	894.8	910.3	857.9	816.9

(3) Other Financial Data

[Billion yen]

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021 forecasts
Cash flows from operating activities	59.8	66.9	41.5	49.4	67.8	-
Cash flows from investing activities	(10.6)	(19.2)	(31.2)	(39.2)	(31.9)	-
Cash flows from financing activities	(24.4)	(32.5)	(25.9)	(37.9)	(7.2)	-
Investments in property, plant and equipment	14.5	6.2	8.6	15.5	20.0	15.7
Depreciation and Amortization Costs	10.5	11.5	11.5	10.9	15.2	13.6
Property, plant and equipment	7.3	7.6	7.1	7.0	11.1	9.8
Intangible assets including intangible assets with products	3.1	4.0	4.4	4.0	4.1	3.8
Ratio of equity attributable to owners of the Company to total assets [%]	87.4	84.2	85.0	81.4	76.9	-
ROE [%]	8.5	6.6	4.2	0.0	(5.6)	-
Basic earnings per share [¥]	127.03	103.35	66.64	0.26	(83.58)	-
Equity attributable to owners of the Company per share [¥]	1,533.91	1,574.26	1,600.64	1,519.22	1,443.99	-

(4) Number of Employees

	End of FY2016	End of FY2017	End of FY2018	End of FY2019	End of FY2020	Forecasts for end of FY2021
Consolidated	7,280	7,187	7,228	6,987	6,728	7,100
Non-consolidated	4,239	4,222	4,111	3,764	3,383	3,420

5 Quarterly Trend

(Amounts less than ¥ 100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2019					FY2020				
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year
Revenue	98.1	90.0	109.3	82.4	379.8	91.8	95.5	102.9	87.6	377.8
	25.8%	23.7%	28.8%	21.7%	100.0%	24.3%	25.3%	27.2%	23.2%	100.0%
Domestic	80.8	73.9	92.6	66.7	314.0	75.7	79.3	86.7	71.3	313.0
	25.7%	23.5%	29.5%	21.3%	100.0%	24.2%	25.3%	27.7%	22.8%	100.0%
Overseas	17.4	16.1	16.7	15.7	65.8	16.1	16.2	16.1	16.3	64.8
	26.4%	24.5%	25.3%	23.8%	100.0%	24.8%	25.1%	24.9%	25.2%	100.0%
Cost of sales	44.8	43.7	54.6	38.0	181.0	45.6	49.2	52.4	43.2	190.4
Sales cost ratio	45.6%	48.6%	49.9%	46.1%	47.7%	49.7%	51.6%	50.9%	49.3%	50.4%
Gross profit	53.3	46.3	54.7	44.5	198.8	46.2	46.3	50.5	44.4	187.4
	26.8%	23.3%	27.5%	22.4%	100.0%	24.7%	24.7%	26.9%	23.7%	100.0%
SG&A expenses, etc.	43.6	44.3	42.3	49.6	179.7	36.6	41.3	40.3	48.1	166.4
	24.3%	24.7%	23.5%	27.6%	100.0%	22.0%	24.8%	24.2%	28.9%	100.0%
R&D expenses	19.9	19.9	17.8	21.9	79.4	15.3	18.6	16.4	22.3	72.6
	25.1%	25.0%	22.4%	27.6%	100.0%	21.1%	25.6%	22.6%	30.7%	100.0%
Core operating profit*	9.8	1.9	12.5	(5.1)	19.1	9.6	5.0	10.2	(3.7)	21.0
	51.2%	10.2%	65.5%	(26.9%)	100.0%	45.5%	23.7%	48.4%	(17.6%)	100.0%
Operating profit*	9.6	2.9	12.4	(31.1)	(6.1)	17.7	(79.6)	7.2	(3.8)	(58.5)
	-	-	-	-	-	-	-	-	-	-
Profit before tax*	9.2	2.9	12.5	(31.1)	(6.5)	17.8	(79.4)	7.1	(3.2)	(57.7)
	-	-	-	-	-	-	-	-	-	-
Net profit attributable to owners of the Company*	6.9	1.4	9.9	(18.1)	0.1	11.5	(62.4)	5.6	(1.6)	(46.9)
	-	-	-	-	-	-	-	-	-	-

Note: The progress rates show in the lower of each cell, except for "cost of sales"

*Brackets indicate expense and loss

(2) Sales Revenue of Main Products

[Billion yen]

	FY2019					FY2020				
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year
Domestic ethical drugs	78.2	71.0	90.5	64.7	304.4	73.3	77.0	84.7	69.7	304.7
	25.7%	23.3%	29.7%	21.3%	100.0%	24.0%	25.3%	27.8%	22.9%	100.0%
Priority products	46.5	42.2	49.1	39.2	177.1	45.3	44.5	49.4	43.8	183.0
	26.3%	23.8%	27.7%	22.2%	100.0%	24.8%	24.3%	27.0%	23.9%	100.0%
Remicade	14.4	13.2	14.9	10.9	53.4	11.9	11.5	12.1	9.9	45.4
	27.1%	24.7%	27.9%	20.4%	100.0%	26.2%	25.4%	26.6%	21.7%	100.0%
Simponi	10.5	9.9	11.2	9.3	41.0	10.7	10.5	11.5	9.6	42.3
	25.7%	24.3%	27.5%	22.6%	100.0%	25.2%	24.9%	27.3%	22.7%	100.0%
Stelara	6.2	6.4	7.8	5.7	26.0	7.0	7.0	9.1	9.2	32.2
	23.8%	24.6%	29.9%	21.8%	100.0%	21.6%	21.7%	28.1%	28.6%	100.0%
Tenelia	4.7	3.4	4.0	3.1	15.2	4.1	3.9	3.9	3.3	15.1
	30.9%	22.3%	26.3%	20.5%	100.0%	27.2%	25.6%	25.6%	21.6%	100.0%
Canaglu	2.2	1.9	2.5	2.3	8.8	2.5	2.5	3.0	2.3	10.3
	24.4%	22.0%	28.1%	25.5%	100.0%	24.6%	24.3%	28.6%	22.5%	100.0%
Canalia	2.2	1.6	1.8	1.2	6.7	2.5	2.5	2.5	2.2	9.7
	32.7%	23.0%	26.1%	18.2%	100.0%	26.1%	25.4%	25.4%	23.1%	100.0%
Vafseo (launched in Aug.)	-	-	-	-	-	-	0.3	0.0	0.0	0.3
	-	-	-	-	-	-	88.1%	7.3%	4.7%	100.0%
Lexapro	3.9	3.6	4.2	3.3	15.0	3.9	3.7	4.2	3.5	15.3
	26.1%	23.8%	27.9%	22.3%	100.0%	25.3%	24.4%	27.7%	22.6%	100.0%
Rupafin	1.3	1.2	1.7	2.6	6.8	1.7	1.6	2.0	3.0	8.2
	18.5%	18.4%	24.6%	38.5%	100.0%	20.4%	19.0%	24.4%	36.2%	100.0%
Imusera	1.1	1.0	1.2	0.9	4.2	1.1	1.0	1.1	0.9	4.1
	27.0%	24.4%	27.7%	20.9%	100.0%	26.8%	25.3%	27.1%	20.9%	100.0%
Vaccines	7.3	8.4	17.2	6.1	39.0	7.5	13.6	14.8	6.7	42.6
	18.7%	21.6%	44.1%	15.6%	100.0%	17.6%	31.9%	34.8%	15.6%	100.0%
Influenza vaccine	(0.0)	1.8	10.6	0.2	12.6	(0.0)	6.4	7.5	0.6	14.4
	(0.1%)	14.3%	84.3%	1.6%	100.0%	(0.2%)	44.1%	52.0%	4.1%	100.0%
Tetrabik	2.4	2.2	2.5	2.4	9.5	2.7	2.5	3.0	2.8	10.9
	25.0%	23.2%	26.5%	25.3%	100.0%	24.5%	22.6%	27.7%	25.3%	100.0%
Mearubik	1.9	1.6	1.3	1.2	6.0	1.9	1.8	1.4	1.1	6.1
	31.9%	27.1%	21.2%	19.8%	100.0%	30.9%	29.5%	22.2%	17.3%	100.0%
JEBIK V	1.5	1.4	1.3	1.0	5.2	1.4	1.5	1.4	0.8	5.2
	29.3%	26.6%	25.1%	19.0%	100.0%	27.9%	28.4%	27.5%	16.1%	100.0%
Varicella vaccine	1.3	1.2	1.3	1.1	4.9	1.3	1.2	1.3	1.2	5.0
	26.2%	24.7%	26.1%	23.1%	100.0%	25.5%	24.8%	26.1%	23.6%	100.0%
Long-listed drugs, etc.	24.3	20.4	24.2	19.4	88.3	20.4	18.9	20.5	19.2	79.0
	27.6%	23.1%	27.4%	22.0%	100.0%	25.8%	23.9%	25.9%	24.3%	100.0%
Overseas ethical drugs	12.6	12.3	12.6	12.2	49.7	12.6	12.5	11.9	13.2	50.2
	25.3%	24.7%	25.4%	24.6%	100.0%	25.2%	24.9%	23.7%	26.3%	100.0%
Radicava	6.1	5.5	5.7	5.8	23.1	5.6	5.5	4.9	6.0	22.0
	26.5%	23.8%	24.8%	24.9%	100.0%	25.4%	25.0%	22.1%	27.4%	100.0%
Royalty revenue, etc.	5.1	4.2	4.4	3.8	17.4	3.8	4.1	4.6	3.5	15.9
	29.0%	23.9%	25.2%	21.9%	100.0%	23.6%	25.6%	29.0%	21.8%	100.0%
Royalty from INVOKANA	2.1	2.0	2.4	2.0	8.5	2.0	2.5	2.8	1.7	9.1
	24.2%	23.9%	28.3%	23.7%	100.0%	22.5%	27.8%	31.2%	18.6%	100.0%
Royalty from GILENYA*1	1.7	1.6	1.4	1.1	5.7	1.1	0.9	1.2	1.2	4.3
	29.3%	27.7%	23.8%	19.2%	100.0%	24.5%	20.5%	26.8%	28.1%	100.0%

Note: The each figure in the lower displays the progress rate.

*1: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

6 State of New Product Development (As of April 25, 2021)

i. Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Filed	Licensed from Horizon Therapeutics (Ireland)
	(Myasthenia gravis)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Filed (Apr. 2021)	Licensed from Neurocrine Biosciences (US)
		Asia Filed	
MT-210 (Roluperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921	Anti-RGMa antibody (Spinal cord injury)	Phase 1	Co-developed with Osaka University (Japan)

ii. Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
	(Systemic sclerosis)	Global Phase 2	
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (IgG4-related disease)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house

※ Asia: Excluding Japan and China

iii. Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2271	Plant-based VLP vaccine (Prophylaxis of seasonal influenza/adults)	Canada Filed (Sep. 2019)	Medicago product (Canada)
		Europe Phase 3	
	(Prophylaxis of seasonal influenza/elderly)	Europe Phase 3	
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	Global Phase 3	Medicago product (Canada)
MT-8972	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-based VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2654	Adjuvanted plant-based VLP vaccine (Prophylaxis of seasonal influenza/elderly)	Phase 1	Medicago product (Canada)

iv. Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
		China Filed (Sep. 2019)	
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Japan Phase 3	In-house
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-3995 (Apararenone)	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe Phase 2	In-house
		Japan Phase 2	
	(Non-alcoholic steatohepatitis: NASH)	Japan Phase 2	
MT-8633/TR1801-ADC	Anti-c-Met ADC* (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

*Antibody drug conjugate

※ Asia: Excluding Japan and China

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of Apr. 25, 2021	Origin/Licensee
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Asia Filed	Taiwan Approved (Feb. 2021)	In-house
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Japan Filed (June 2020)	Japan Approved (Mar. 2021)	Licensed from Horizon Therapeutics (Ireland)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Phase 2/3	Japan Filed (Apr. 2021)	Licensed from Neurocrine Biosciences (US)
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	Global Phase 2	Global Phase 3	Medicago product (Canada)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Systemic sclerosis)	None	Global Phase 2	In-house
MT-4129	Cardiovascular system, etc.	Phase 1	Licensed to Mineralys Therapeutics (US)	In-house
MT-1303 (Amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe Phase 2	Deleted (Discontinued)	In-house
	(Crohn's disease)	Japan Phase 2	Deleted (Discontinued)	
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe Phase 2	Deleted (Discontinued)	In-house

※ Asia: Excluding Japan and China